share_log

BRIEF-Sarepta Therapeutics Says Investigational Gene Therapy SRP-9003 Shows Sustained Expression And Functional Improvements 2

BRIEF-Sarepta Therapeutics Says Investigational Gene Therapy SRP-9003 Shows Sustained Expression And Functional Improvements 2

Brief-Sarepta Treeutics表示，研究性基因治疗SRP-9003显示持续表达和功能改善2
路透社 ·  2021/03/19 06:13

March 18 (Reuters) - Sarepta Therapeutics Inc :
   * SAREPTA THERAPEUTICS’ INVESTIGATIONAL GENE THERAPY SRP-9003 FOR THE TREATMENT OF LIMB-GIRDLE MUSCULAR DYSTROPHY TYPE 2E SHOWS SUSTAINED EXPRESSION AND FUNCTIONAL IMPROVEMENTS 2 YEARS AFTER ADMINISTRATION
   * SAREPTA THERAPEUTICS INC - RESULTS IN BOTH COHORTS CONTINUE TO REINFORCE SAFETY AND TOLERABILITY PROFILE OF SRP-9003

Source text for Eikon:  Further company coverage:

((Reuters.Briefs@thomsonreuters.com;)

路透3月18日电-Sarepta治疗公司：*Sarepta Treeutics用于治疗2E型肢体带状肌营养不良症的研究性基因疗法SRP-9003在用药2年后显示持续表达和功能改善*Sarepta Treateutics Inc-两个队列的结果继续加强SRP-9003的安全性和耐受性Eikon的源文本：进一步的公司报道：(Reurs.Briefs@thomsonreurs.com；)

译文内容由第三方软件翻译。


以上内容仅用作资讯或教育之目的，不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。
    抢沙发